Product Details

Uniprot No.

Target Names

Alternative Names

Tumor necrosis factor receptor superfamily member 12A (Fibroblast growth factor-inducible immediate-early response protein 14) (FGF-inducible 14) (Tweak-receptor) (TweakR) (CD antigen CD266), TNFRSF12A, FN14

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human TWEAKR

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

7H8

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid

Tested Applications

ELISA, WB, IHC

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200

Protocols

ELISA Protocol
Western Blotting(WB) Protocol
Immunohistochemistry (IHC) Protocol

Troubleshooting and FAQs

Antibody FAQs

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Description

TNFRSF12A, also known as Fn14 or TWEAK receptor, serves as a critical mediator of inflammatory signaling and tissue remodeling pathways. This type I transmembrane receptor binds TWEAK (TNF-like weak inducer of apoptosis) to activate NF-κB and MAPK cascades, influencing cell survival, proliferation, and migration. Its expression is typically low in healthy tissues but becomes markedly upregulated in response to injury, inflammation, and malignancy, making it a compelling target for researchers investigating tumor progression, cardiovascular pathology, and signal transduction mechanisms.

This recombinant monoclonal antibody, clone 7H8, offers the reproducibility and consistency that demanding experimental workflows require. Generated against a synthetic peptide derived from human TWEAKR and produced in rabbit host, the recombinant format ensures sequence-defined specificity with minimal lot-to-lot variation, allowing you to confidently compare results across extended studies.

Validation studies confirm reliable performance across multiple applications. In western blot analysis, the antibody detects TNFRSF12A at the expected 14 kDa molecular weight in human glioblastoma cell lines U251 and U87, as well as MCF-7 breast cancer cells, with recommended dilutions ranging from 1:500 to 1:5000. For tissue-based studies, immunohistochemistry validation demonstrates clear staining in paraffin-embedded human placenta sections at 1:100 dilution, confirming utility for examining TNFRSF12A expression patterns in fixed specimens.

Whether you are exploring TWEAK-Fn14 axis contributions to tumor microenvironment dynamics, investigating cardiac remodeling processes, or characterizing downstream signaling events, this affinity-purified antibody provides a dependable tool for advancing your research objectives.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Target Background

Function

Receptor for TNFSF12/TWEAK. Weak inducer of apoptosis in some cell types. Promotes angiogenesis and the proliferation of endothelial cells. May modulate cellular adhesion to matrix proteins.

Gene References into Functions

Expression level of Fn14 was significantly associated with overall survival and disease-free survival in low-grade gliomas. Fn14 was an independent predictive biomarker for the progression and prognosis in low-grade gliomas. PMID: 29741404
TWEAK/Fn14 interaction induces proliferation and migration in human airway smooth muscle cells via activating the NF-kappaB pathway PMID: 29143982
Data demonstrated that the Src/Fn14/NF-kappaB axis plays a critical role in NSCLC metastasis. PMID: 29500337
Results show that Fn14 expression is high compared in non-small cell lung cancer compared to normal lung tissues. In addition, high Fn14 expression is associated with poor prognosis in lung adenocarcinoma. PMID: 29251323
TWEAK/Fn14 contributes to endothelial dysfunction through modulation of reactive oxygen species (ROS), and mitochondrial ROS. PMID: 29257217
Expression of the TWEAK-Fn14 axis was upregulated in patients with autoimmune thyroid disease and might play a role in the pathogenesis of autoimmune thyroid disease. PMID: 28636775
Data suggest that expression of Fn14 on a tumor can initiate cachexia; an antibody against Fn14 may be an effective antineoplastic agent. [REVIEW] PMID: 27254081
The results suggest that TWEAK/Fn14 interaction directly favors inorganic phosphate-induced vascular smooth muscle cells calcification by activation of both canonical and non-canonical NF-kappaB pathways. PMID: 27441657
TWEAK upregulated the expression of Fn14. PMID: 28411440
Fn14.TRAIL can be converted into a highly effective TRAIL oligomer upon binding to TWEAK which induces lymphoblast apoptosis. PMID: 28455246
Data show that aurintricarboxylic acid (ATA) targets the TNF-related WEAK inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling axis, which could potentially be developed as a new therapeutic agent for treatment of glioblastoma (GBM) patients. PMID: 28103571
TNFRSF12A was knocked down in the SMMC7721 cell line through siRNA. This demonstrated that cells exhibited reduced reproductive and metastatic capacity ex vivo. PMID: 28138696
In this review article, we summarize studies indicating that (i) Fn14 gene expression is low in normal brain tissue but is upregulated in advanced brain cancers and, in particular, in GB tumors ; TWEAK: Fn14 engagement as well as Fn14 overexpression can stimulate glioma cell migration, invasion and resistance to chemotherapeutic agents in vitro. PMID: 26300004
Fn14 is a receptor of mitogen TWEAK (tumor necrosis factor-like weak inducer of apoptosis), expressed on the membranes of HPCs and promoting their proliferation. PMID: 28180936
EGFR Del 19 may promote Fn14 and JAK1/STAT1 expression in NSCLC. PMID: 27350337
TWEAK/Fn14 activation induces keratinocyte proliferation under psoriatic inflammation PMID: 26264384
The results demonstrated that vitreous fluid from patients with PDR had higher levels of TWEAK and Fn14 than that from T2DM patients without PDR, thus suggesting an important regulatory role of TWEAK/Fn14 signaling in the pathogenesis of PDR. PMID: 27051016
Results indicate that FN14 and GRP94 are prediction/prognosis markers which open up new possibilities for preventing/treating brain metastasis in breast cancer patients. PMID: 26497551
Evidence that higher tumor Fn14 expression is required for pharmacodynamic response to the anti-TWEAK monoclonal antibody RG7212 in patients with Fn14-positive solid tumors. PMID: 26446946
Fn14 has multiple roles in tumor metastasis. (Review) PMID: 26592249
TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. PMID: 26224570
Activated Fn14 expression increases extracellular matrix synthesis and fibroblast activation. Activation of Fn14 is done by the TGF-beta signaling pathway through the transcription factor SMAD4. PMID: 26625141
Fn14 modulates cell growth and drug resistance by upregulating Bcl-xl expression through the NF-kappaB pathway. PMID: 25054270
Results indicate that oncogenic Src may contribute to Fn14 overexpression in solid tumors, and that Src mediated cell invasion could potentially be inhibited with Fn14- targeted therapeutics. PMID: 25392346
HPV type 16 infections keratinocytes turns from apoptosis to proliferation cycle under FN14 protein influence. PMID: 26016896
The first human data to show a transient activation of the TWEAK-Fn14 axis. PMID: 25539934
TWEAK-Fn14 axis may be involved in the pathogenesis of polymyositis and dermatomyositis PMID: 24467773
TweakR protein was expressed in about half of human breast cancer samples PMID: 25375638
abundantly expressed in the dermal vessel wall of lesional skin in patients with urticarial vasculitis but not controls PMID: 23968277
Results position TWEAK-Fn14 signaling through Mcl-1 as a significant mechanism for NSCLC tumor cell survival PMID: 24469836
results define one upstream mechanism, via FN14 signaling, through which the NFkappaB pathway contributes to prostate cancer metastasis. PMID: 24970477
Receptor-targeted therapeutics for both MET and FN14 are in clinical development, the use of which may mitigate the metastatic potential of NSCLC. PMID: 24710956
insight into the Fn14 signaling mechanism PMID: 23750247
High FN14 expression is associated with resistance to 5-fluorouracil in gastric cancer. PMID: 24337061
a model in which constitutive down-regulation of Fn14 facilitates dynamic regulation of Fn14 protein levels and prevents spontaneous or inappropriate receptor signaling. PMID: 24652288
We found that the TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor inducible-14 (Fn14) pathway is involved in the development of pathologic retinal neovascularization. PMID: 24408972
These new findings of the effect of Fn14 on valvular interstitial cell-like differentiation may provide a novel therapeutic strategy for heart valve disease treatment. PMID: 24122208
Increased podocyte Fn14 expression is associated with proteinuric kidney disease. PMID: 23999007
Fn14 overexpression is associated with hepatocellular carcinoma. PMID: 23886137
Induced overexpression of Fn14 levels in MCF7 cells through HER2 (ERBB2) signaling translated to an improved therapeutic index of hSGZ treatment. PMID: 23722548
Fn14 protein may have a role in breast carcinoma progression PMID: 23300011
results validate the TWEAK-Fn14 interaction as a chemically tractable target and provide the foundation for further exploration utilizing chemical biology approaches focusing on validating this system as a therapeutic target in invasive cancers. PMID: 24056367
The Fn14/TWEAK pathway contributes to the endothelial steps of neuroinflammation. PMID: 23320797
The expression of TWEAK and Fn14 in neuroblastoma suggests that TWEAK functions as an important regulator of primary neuroblastoma growth, invasion and survival. PMID: 23443741
TWEAK/Fn14, by activating macrophages, could be ovarian tumor suppressors. PMID: 23469193
we show that TWEAK/Fn14 can signal through the JAK-STAT pathway to induce interferon-beta, and that the ability of TWEAK to induce tumor cell apoptosis is mediated by JAK-STAT signaling. PMID: 23107828
TWEAK binds to hFn14 by surface plasmon resonance (View interaction) xeFn14 binds to TWEAK by enzyme linked immunosorbent assay PMID: 23438059
LCN2 and TWEAKR-TWEAK as crucial downstream effectors of NFAT1 that regulate breast cancer cell motility and invasive capacity. PMID: 22767506
Fn14, the receptor for TNF-like weak inducer of apoptosis, is selectively upregulated in patients with Alcoholic Hepatitis. PMID: 22637703
TWEAK/Fn14 can regulate expression and secretion of HMGB1 in monocytes/macrophages, participating in the inflammatory response associated with atherosclerotic plaque development. PMID: 23288170

Hide All

Subcellular Location

Membrane; Single-pass type I membrane protein.

Tissue Specificity

Highly expressed in heart, placenta and kidney. Intermediate expression in lung, skeletal muscle and pancreas.

Database Links

HGNC: 18152

OMIM: 605914

KEGG: hsa:51330

STRING: 9606.ENSP00000326737

UniGene: Hs.355899

Message

Product >> Product Name：
Product >> Code：
Name： *
Email： *
Company/Organization：
Phone：
Since emails may get flagged by spam filters occasionally, we recommend leaving your phone number as a precaution. Your information is safe with us.
Question/Comment： *
Your Region： *
I'd like to receive email newsletters from Cusabio

Yes

No
How do you know CUSABIO?

Email

Distributor

Search engine

Advertisement

Others
CAPTCHA verification：
Please enter the characters shown. Click the image to refresh if unclear.

Code	CSB-RA441307A0HU
Size	US$210
	Order now
Image	Western Blot Positive WB detected in: U251 whole cell lysate, MCF-7 whole cell lysate, U87 whole cell lysate All lanes: TNFRSF12A antibody at 1:2000 Secondary Goat polyclonal to rabbit IgG at 1/50000 dilution Predicted band size: 14, 11 kD Observed band size: 14 kDa IHC image of CSB-RA441307A0HU diluted at 1:100 and staining in paraffin-embedded human placenta tissue performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.
Have Questions?	Leave a Message or Start an on-line Chat

TNFRSF12A Recombinant Monoclonal Antibody

Product Details

Related Products

Customer Reviews and Q&A

Target Background